KR102531666B1 - Composition for diagnostic african swine fever using two recombinant antigens and diagnostic kits comprising thereof - Google Patents

Abstract

The present invention relates to an antigen composition for diagnosing African swine fever virus (ASFV) containing two recombinant antigens for diagnosing African swine fever virus (ASFV) infection, a kit for diagnosing African swine fever using the same, and a composition for diagnosing African swine fever It relates to a method for providing information. By detecting African swine fever antibodies using the antigen composition of the present invention, diagnostic accuracy is excellent, and it is provided as a kit, which is simple and quick to use.

Description

Antigen composition for diagnosis of African swine fever using two recombinant antigens and diagnostic kit containing the same

The present invention is an antigen composition for diagnosing African swine fever virus (ASFV) using two recombinant antigens to diagnose African swine fever virus (ASFV) infection, a kit for diagnosing African swine fever including the same, and a composition for diagnosing African swine fever It is about how information is provided.

African swine fever (ASF) is an infectious disease of pigs caused by infection with the African swine fever virus (ASFV) belonging to the Asfarviridae family. After the first occurrence was reported in Kenya in 1921, there were reports of occurrence mainly in the sub-Saharan region, and since 2007, the extent of occurrence in regions outside of Africa such as Georgia, Armenia, and Azerbaijan, along the Black Sea coast started to increase. In particular, recently, the outbreak has been spreading from Russia to the east and west, and cases of outbreaks in China and Southeast Asia, which have many exchanges with Korea, are rapidly increasing.

African swine fever virus is highly resistant to the general environment. The infectivity of African swine fever virus is maintained for more than 18 months at room temperature and for more than 6 months in meat products such as ham. In addition, it is known that it is very strong against heat and has a characteristic that infectivity disappears only when exposed to 56 ° C for at least 1 hour.

Although African swine fever is a serious disease with a mortality rate of up to 100% when infected with pigs, there is no commercially available vaccine for this disease. As African swine fever spreads again in Europe and spreads to the Asian continent, attention is focused on the development of vaccines that have not progressed properly in the past. However, due to safety issues, the development of live attenuated vaccines is limited, and previous experimental studies have not been successful. There are many obstacles to overcome in developing a dead poison vaccine that is effective in defense. For example, ASFV has a larger and more complex structure than other viruses, so the effective site for incapacitating it is not clearly known.

African swine fever virus has 10 times as many genes as common RNA viruses. Since the gene is large, there are many types of proteins that can be made from the gene, and the ASFV genome is known to encode at least 151 ORFs. African swine fever virus has a large number of structural proteins, and the size of the virus itself is much larger than other viruses. It reaches 5 times its size. As the African swine fever virus is large and complex, immunity is difficult, so no effective vaccine has yet been developed.

Diagnostic tests are essential to confirm the diagnosis of African swine fever. Diagnostic tests include methods for detecting ASFV in blood and internal organs or detecting antibodies in the serum of infected pigs. If testing for antibodies, the sample should ideally be serum from infected pigs in the convalescent phase between 8 and 21 days post infection. The antibody detection method using the serum of infected pigs is performed by first screening using a commercially available enzyme-linked immunosorbent assay (ELISA), etc., followed by an immunoblot test (IB), an immuno-peroxidase test (immuno- Peroxidase test; IPT) and indirect fluorescence antibody method (Indirect Immunofluorescence; IFA) can be used for final evaluation. Because ASF progresses rapidly and varies, and pigs with subclinical infection may also exist, the laboratory must perform both antigen and antibody tests to accurately determine the presence of infection.

Accordingly, there is an urgent need to develop a related technology that can be provided commercially, is easy to use, and can quickly and accurately diagnose whether or not ASFV is infected.

Accordingly, the present inventors have endeavored to produce an antigen composition capable of diagnosing African swine fever (ASF) infection quickly, simply, and with high accuracy, and a kit for diagnosing African swine fever using the same.

As a result, a diagnostic antigen composition using a peptide comprising the amino acid sequence of SEQ ID NO: 7 and a peptide comprising the amino acid sequence of SEQ ID NO: 8, and a kit containing the same can diagnose African swine fever quickly, simply and with high accuracy. confirmed.

Accordingly, an object of the present invention is to provide an antigen composition for diagnosis of African swine fever (ASF).

Another object of the present invention is to provide a vector for expressing African swine fever antigen protein.

Another object of the present invention is to provide a primer set composition for amplifying a nucleotide sequence encoding an African swine fever (ASFV) antigen protein.

Another object of the present invention is to provide a kit for diagnosing African swine fever.

Another object of the present invention is to provide an information providing method for diagnosing African swine fever.

The present invention relates to an antigen composition for diagnosing African swine fever (ASF), a kit for diagnosing African swine fever including the same, and a method for providing information for diagnosing African swine fever.

Hereinafter, the present invention will be described in more detail.

An example of the present invention is a peptide comprising the amino acid sequence of SEQ ID NO: 7; and

It relates to an antigen composition for diagnosis of African swine fever (ASF) comprising: a peptide comprising the amino acid sequence of SEQ ID NO: 8.

In the present invention, the peptide comprising the amino acid sequence of SEQ ID NO: 7 may be a recombinant antigenic protein derived from p22, a structural protein of African swine fever virus.

In the present invention, the peptide comprising the amino acid sequence of SEQ ID NO: 8 may be a recombinant antigenic protein derived from p30, a structural protein of African swine fever virus.

The recombinant antigen protein may be a peptide comprising the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 8, for example, about 70% or more, about 80% or more, about 90% or more, about 95% or more, about It may be a functionally equivalent protein having a homology of 98% or more, or about 99% or more.

In the present invention, the concentration of the peptide comprising the amino acid sequence of SEQ ID NO: 7 included in the antigen composition is 0.3 to 0.7 ug/mL, 0.3 to 0.6 ug/mL, 0.4 to 0.7 ug/mL, 0.4 to 0.6 ug/mL or 0.5 It may be ug/mL, for example, 0.5 ug/mL, but is not limited thereto.

In the present invention, the concentration of the peptide comprising the amino acid sequence of SEQ ID NO: 8 included in the antigen composition is 0.7 to 1.3 ug/mL, 0.7 to 1.2 ug/mL, 0.7 to 1.1 ug/mL, 0.8 to 1.3 ug/mL, 0.8 to 1.2 ug/mL, 0.8 to 1.1 ug/mL, 0.9 to 1.3 ug/mL, 0.9 to 1.2 ug/mL, or 0.9 to 1.1 ug/mL, for example, 1.0 ug/mL, but It is not limited.

In one embodiment of the present invention, the concentration of the peptide comprising the amino acid sequence of SEQ ID NO: 7 included in the antigen composition may be 0.5 ug/mL, and the concentration of the peptide comprising the amino acid sequence of SEQ ID NO: 8 may be 1.0 ug/mL. .

Another example of the present invention is a first recombinant vector comprising the nucleotide sequence of SEQ ID NO: 5; And a second recombinant vector comprising the nucleotide sequence of SEQ ID NO: 6; relates to a vector for expressing African swine fever (ASF) antigen protein.

The nucleotide sequence of SEQ ID NO: 5 may be a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 7.

The nucleotide sequence of SEQ ID NO: 6 may be a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 8.

As used herein, the term "vector" means a means for expressing a gene of interest in a host cell. Examples include viral vectors such as plasmid vectors, cosmid vectors and bacteriophage vectors, adenoviral vectors, retroviral vectors and adeno-associated viral vectors. Vectors that can be used as the recombinant vector are plasmids often used in the art (eg, pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8/9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14 , pGEX series, pET series, and pUC19, etc.), phages (eg, λgt4λ, λ-Charon, λΔz1, and M13, etc.) or viruses (eg, SV40, etc.), but are not limited thereto.

In the present invention, a recombinant vector can typically be constructed as a vector for cloning or a vector for expression. An expression vector may be a conventional vector used in the art to express foreign proteins in plants, animals, or microorganisms. In addition, the recombinant vector can be constructed through various methods known in the art.

In the present invention, the recombinant vector can be constructed using a prokaryotic cell or a eukaryotic cell as a host. For example, when the vector used is an expression vector and a prokaryotic cell is used as a host, a strong promoter capable of promoting transcription (e.g., pLλ promoter, CMV promoter, trp promoter, lac promoter, tac promoter, T7 promoter, etc.), a ribosome binding site for initiation of translation, and a transcription/translation termination sequence. In the case of using a eukaryotic cell as a host, the origin of replication operating in the eukaryotic cell included in the vector includes the f1 origin of replication, the SV40 origin of replication, the pMB1 origin of replication, the adeno origin of replication, the AAV origin of replication and the BBV origin of replication, etc. It is not limited. In addition, promoters derived from the genome of mammalian cells (eg, metallotionine promoter) or promoters derived from mammalian viruses (eg, adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, The cytomegalovirus promoter and the tk promoter of HSV) can be used, and usually have a polyadenylation sequence as a transcription termination sequence.

Hosts may include, for example, Escherichia coli, yeast, animal cells, plant cells, or insect cells. Prokaryotes include, for example, E. coli JM109, E. coli BL21, E. coli RR1, E. coli LE392, E. coli B, E. coli X 1776, E. coli W3110, Bacillus subtilis, Bacillus chew There are strains of the genus Bacillus, such as Lingensis, and intestinal bacteria and strains, such as Salmonella typhimurium, Serratia marcessons, and various Pseudomonas species. In case of transformation into eukaryotic cells, as host cells, yeast (Saccharomyce cerevisiae), insects cells, plant cells and animal cells, such as Sp2/0, CHO (Chinese hamster ovary) K1, CHO DG44, PER.C6, W138, BHK, COS7, 293, HepG2, Huh7, 3T3, RIN, MDCK cell lines, etc. This may be used, but is not limited thereto.

In the present invention, the nucleotide sequence of SEQ ID NO: 5 or a nucleotide sequence having substantial identity thereto; and a nucleotide sequence of SEQ ID NO: 6 or a nucleotide sequence substantially identical thereto; each may be introduced into one vector.

As used herein, the term "substantial identity" means that each nucleotide sequence and any other nucleotide sequence are aligned so as to correspond as much as possible, and the sequence is analyzed so that any other nucleotide sequence is 70% or more, 90% or more with each nucleotide sequence. , or having 98% or more sequence homology.

Another example of the present invention is a first primer set comprising a forward primer of SEQ ID NO: 1 and a reverse primer of SEQ ID NO: 2; And a second primer set comprising a forward primer of SEQ ID NO: 3 and a reverse primer of SEQ ID NO: 4;

It relates to a primer set composition for amplifying a nucleotide sequence encoding an African swine fever (ASF) antigen protein.

The nucleotide sequence encoding the amplified African swine fever antigen protein may be introduced into a vector for expressing the African swine fever (ASF) antigen protein.

In one embodiment of the present invention, the first primer set including the forward primer of SEQ ID NO: 1 and the reverse primer of SEQ ID NO: 2 may be specific for a nucleotide sequence encoding p22, a structural protein of African swine fever virus.

In one embodiment of the present invention, the second primer set including the forward primer of SEQ ID NO: 3 and the reverse primer of SEQ ID NO: 4 may be specific for a nucleotide sequence encoding p30, a structural protein of African swine fever virus.

As used herein, the term "primer" refers to a condition in which synthesis of a primer extension product complementary to a nucleic acid strand (template) is induced, that is, in the presence of nucleotides and a polymerizing agent such as DNA polymerase, and at a suitable temperature. And it may mean an oligonucleotide that can act as a starting point of synthesis at pH.

The primer set compositions of the present invention may incorporate additional features that do not alter the basic properties of the primers in question. Additional characteristics may refer to, but is not limited to, naturally occurring dNMPs (i.e., dAMP, dGMP, dCMP and dTMP), modified nucleotides, or non-natural nucleotides.

The primer must be long enough to prime the synthesis of the extension product in the presence of the polymerization agent. The exact length of the primer will depend on a number of factors including, for example, temperature, application and source of the primer.

As used herein, the term "annealing" or "priming" refers to the apposition of an oligodeoxynucleotide or nucleic acid to a template nucleic acid, wherein the apposition is such that a polymerase polymerizes the nucleotides to form a nucleic acid complementary to the template nucleic acid or a portion thereof. to form molecules.

The primer used in the present invention may be hybridized or annealed to one site of the template to form a double-stranded structure.

As used herein, the term "hybridization" means that complementary single-stranded nucleic acids form a double-stranded nucleic acid. Hybridization can occur between two nucleic acid strands that are completely identical or substantially identical with some mismatches. Complementarity for hybridization may vary depending on hybridization conditions, particularly temperature. There is no difference between the terms "annealing" and "hybridization" in the present specification and are used interchangeably in the present specification.

In one embodiment of the present invention, the primer set composition including the forward primer of SEQ ID NO: 1 and the reverse primer of SEQ ID NO: 2 may complementarily bind to the nucleotide sequence of SEQ ID NO: 5 encoding the p22 antigen protein.

In one embodiment of the present invention, the primer set composition including the forward primer of SEQ ID NO: 3 and the reverse primer of SEQ ID NO: 4 may complementarily bind to the nucleotide sequence of SEQ ID NO: 6 encoding the p30 antigen protein.

Another embodiment of the present invention relates to a kit for diagnosing African swine fever (ASF).

In the present invention, the diagnostic kit includes a peptide comprising the amino acid sequence of SEQ ID NO: 7; And a peptide comprising the amino acid sequence of SEQ ID NO: 8; may include, but is not limited thereto.

In the present invention, the concentration of the peptide containing the amino acid sequence of SEQ ID NO: 7 included in the kit is 0.3 to 0.7 ug/mL, 0.3 to 0.6 ug/mL, 0.4 to 0.7 ug/mL, 0.4 to 0.6 ug/mL or 0.5 ug /mL may be, for example, 0.5 ug/mL, but is not limited thereto.

In the present invention, the concentration of the peptide comprising the amino acid sequence of SEQ ID NO: 8 included in the kit is 0.7 to 1.3 ug / mL, 0.7 to 1.2 ug / mL, 0.7 to 1.1 ug / mL, 0.8 to 1.3 ug / mL, 0.8 to It may be 1.2 ug/mL, 0.8 to 1.1 ug/mL, 0.9 to 1.3 ug/mL, 0.9 to 1.2 ug/mL, or 0.9 to 1.1 ug/mL, for example, 1.0 ug/mL, but is not limited thereto. it is not going to be

In one embodiment of the present invention, the concentration of the peptide containing the amino acid sequence of SEQ ID NO: 7 included in the kit may be 0.5 ug/mL, and the concentration of the peptide containing the amino acid sequence of SEQ ID NO: 8 may be 1.0 ug/mL.

In the present invention, the kit may have a peptide coated on its surface.

In the present invention, the kit may use an antigen-antibody reaction.

In the present invention, the kit may diagnose whether or not infected with African swine fever virus type I, type II, or both types I and II at the same time.

In the present invention, the kit may further include a chromogenic enzyme.

In the present invention, the coloring enzyme is Q dot (Quantum dot), HRPO (Horseradish peroxidase), basic dephosphorylation enzyme (Alkaline phosphatase), glucose oxidase (Glucose Oxidase), luciferase (luciferase), beta-D-galacto Sidase (β malate dehydrogenase (MDH) and one enzyme selected from the group consisting of acetylcholinesterase (acetylcholinesterase) and protein A may be conjugated (conjugation), for example, HRPO and protein A may be conjugated HRPO conjugate (HRPO conjugate), but is not limited thereto.

In one embodiment of the present invention, the HRPO conjugate is produced by conjugating Protein A (Microprotein, cat. no. A100L20) and horseradish peroxidase (HRP) with Protein A. it could be

The HRPO conjugate may exhibit a color reaction by binding to an antibody against a specific antigen in a specimen. At this time, if color development does not appear, it means that there is no antibody against the specific antigen reacting with the conjugate in the specimen. That is, if there is no antibody in the sample, no antibody binds to the antigen protein coated on the surface of the kit and no color reaction occurs.

In one embodiment of the present invention, the kit may further include HRPO conjugate (Horseradish peroxidase conjugate).

Another example of the present invention relates to a method for providing information for diagnosing African swine fever (ASF), which includes the following steps:

preparation step of preparing a sample; and

A contact step of contacting a sample with a peptide comprising the amino acid sequence of SEQ ID NO: 7 and a peptide comprising the amino acid sequence of SEQ ID NO: 8.

In the present invention, the sample is at least one virus selected from the group consisting of African swine fever virus type I (ASFV type I) and African swine fever virus type II (ASFV type II), and antibodies thereof. It may contain.

In the present invention, the sample may be separated from at least one selected from the group consisting of blood, plasma, serum, lymph, urine, tears, synovial fluid, saliva, wound fluid, and cerebrospinal fluid, and, for example, separated from serum It may be, but is not limited thereto.

In the present invention, the contacting step may be contacting a sample with a peptide comprising the amino acid sequence of SEQ ID NO: 7 and a peptide comprising the amino acid sequence of SEQ ID NO: 8. Through this, an antigen-antibody reaction may proceed.

In the present invention, the contacting step is 20 to 30 ℃, 20 to 29 ℃, 20 to 28 ℃, 21 to 30 ℃, 21 to 29 ℃, 21 to 28 ℃, 22 to 30 ℃, 22 to 29 ℃ or 22 to 28 ℃ It may be performed at a temperature condition of ℃, for example, it may be performed at a temperature condition (room temperature) of 22 to 28 ℃, but is not limited thereto.

In one embodiment of the present invention, the information providing method may further include a color development step of contacting the sample subjected to the contact step with a color enzyme.

In one embodiment of the present invention, the chromogenic enzyme may be a HRPO conjugate in which Horseradish peroxidase (HRPO) and Protein A are conjugated.

The HRPO conjugate may exhibit a color reaction by binding to an antibody against a specific antigen in a specimen. At this time, if color development does not appear, it means that there is no antibody against the specific antigen reacting with the conjugate in the specimen. That is, if a color reaction does not appear in the color development step, it means that there is no antibody in the sample.

The information providing method of the present invention can provide information by simply and quickly confirming whether a subject is infected with African swine fever by confirming whether an antibody of African swine fever virus is present in a sample.

The present invention relates to an antigen composition for diagnosing African swine fever virus (ASFV) containing two recombinant antigens for diagnosing African swine fever virus (ASFV) infection, a kit for diagnosing African swine fever using the same, and a composition for diagnosing African swine fever It relates to a method for providing information. By detecting African swine fever antibodies using the antigen composition of the present invention, diagnostic accuracy is excellent, and it is provided as a kit, which is simple and quick to use.

1 is a schematic diagram showing a site to be expressed in a recombinant antigen from antigen proteins p22 and p30 according to an experimental example of the present invention.
2a and 2b show electrophoresis to confirm whether plasmids containing the nucleotide sequences encoding p22 and p30 were introduced into DH5a E. coli according to an experimental example of the present invention.
3a and 3b are SDS-PAGE photographs confirming the expression of recombinant p22 and p30 proteins according to an experimental example of the present invention.
4a and 4b are SDS-PAGE photographs of purified recombinant p22 and p30 proteins according to an experimental example of the present invention.
Figure 5 shows the results of measuring reactivity using the kit of the present invention with respect to ASFV gene type II (separation from Paju).
6a to 6c show the reactivity measurement results using commercially available conventional kits (ID Screen Confirmation ELISA, ID Screen Competition ELISA, and Ingezim PPA COMPAC ELISA) for ASFV gene type II (separation from Paju).
Figure 7 shows the results of measuring reactivity using the kit of the present invention with respect to ASFV gene type I (OURT 88/3).
8a to 8c show reactivity measurement results using commercially available conventional kits (ID Screen Confirmation ELISA, ID Screen Competition ELISA, and INgezim PPA COMPAC ELISA) for ASFV gene type I (OURT 88/3).
Figure 9 shows the results of measuring reactivity using the kit of the present invention with respect to antiserum in areas where ASFV does not occur.

Hereinafter, the present invention will be described in more detail through experimental examples. These experimental examples are only for explaining the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these experimental examples according to the gist of the present invention. .

Experimental Example 1. ASFV recombinant antigen gene cloning

For the expression of p22 and p30, which are structural proteins of African swine fever virus (ASFV), 20 ul of DNA samples were prepared from Estonia-2014 using AccuPower ^® ProFi Taq PCR PreMix. The sites of p22-TM and p30 to be expressed are schematically shown in FIG. 1 .

Polymerase chain reaction (PCR) of the nucleotide sequences encoding p22 and p30 was denaturation (94 ℃, 30 seconds), annealing (55 ℃, 30 seconds), extension (extension ( 72 °C, 60 seconds) to configure a total of 30 cycles by configuring one cycle, and after performing the last cycle, it was maintained at 72 °C for 5 minutes. ASFV recombinant antigen primer sequences used for PCR amplification are shown in Table 1.

sequence number denomination Sequence Listing (5` -> 3`) note One ASFV p22 Forward CGGGATCCTATAAGAAACAACAACCACCGA △Transmembranes 2 ASFV p22 Reverse CCCTCGAGTGCATGTTTATGATTTCTAGGT 3 ASFV p30 Forward AACGGATTTAAGATCATCTTCACAAGTTGTGTTTCATGCGGGTAG 4 ASFV p30 Reverse CTACCCGCATGAAACACAACTTGTGAAGATGATCTTAAATCCGTT

The synthesized p22-TM and p30 gene fragments were cloned into p22-TM using BamHI·XhoI, a restriction enzyme site present in the MCS (multiple coloning site) of the pET32a (Novagen) vector, respectively, and then using EcoRI·SalI. to clone p30. Transformation was performed by inserting into DH5a E. coli using heat shock. Thereafter, the sequence of the transgene was confirmed by extracting the plasmid DNA and treating it with a restriction enzyme, and the results are shown in FIGS. 2a and 2b.

The sequences of transgenes are shown in Table 2.

sequence number denomination Sequence Listing (5'->3') note 5 p22-TM
nucleotide ATGAGCGATAAAATTATTCACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCG GACGGGGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGTGCAAAATGATCGCC CCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAACTGACCGTTGCAAAACTGAAC ATCGATCAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTATCCCGACTCT GCTG CTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGTGCACTGTCTAAAGGTCAGTTG AAAGAGTTCCTCGACGCTAACCTGGCCGGTTCTGGTTCTGGCCATATGCACCATCATCATCATCATTCTTCTGGTCTGGTGCCACGCGGTTCTGGTATGAAAGAAACCGCTGCTGCTAAA TTCGAACGCCAGCACATGGACAGCCCAGATCTGGGTACCGACGACGACGACAAGGCCAT G GCTGATATCGGATCCTATAAGAAACAACAACCACCGAAAAAGGTCTGTAAAGTAGATAAA GATTGTGGTAGTGGAGAGCATTGTGTTCGTGGATCATGTAGCTCATTGAGCTGCTTAGAT GCCGTAAAAATGGACAAACGAAATATTAAGATAGATTCTAAGATTTCCTCATGCGAATTC ACTCCCAATTTTTACCGTTTTACGGATACTGCTGCTGATGAGCAGCAAGAATTTGGAAAAC CACCACTGA 969 n.t. 6 p30
nucleotide ATGAGCGATAAAATTATTCACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCG GACGGGGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGTGCAAAATGATCGCC CCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAACTGACCGTTGCAAAACTGAAC ATCGATCAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTATCCCGACTCT GCTG CTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGTGCACTGTCTAAAGGTCAGTTG AAAGAGTTCCTCGACGCTAACCTGGCCGGTTCTGGTTCTGGCCATATGCACCATCATCATCATCATTCTTCTGGTCTGGTGCCACGCGGTTCTGGTATGAAAGAAACCGCTGCTGCTAAA TTCGAACGCCAGCACATGGACAGCCCAGATCTGGGTACCGACGACGACGACAAGGCCAT T ATACTGAACATCAGGCTCAAGAAGAATGGAATATGATTCTGCATGTGCTGTTTGAAGAG GAGACGGAATCCTCAGCATCTTCGGAGAACATTCATGAAAAAAATGATAATGAAACCAAT GAATGCACATCCTCCTTTGAAACGTTGTTTGAGCAAGAGCCCTCATCGGAGGTACCTAAA GACTCCAAGCTGTATATGCTTGCACAAAAGACTGTGCAACATATTGAACAATATGGAAAG GCACCTG ATTTTAACAAGGTTATTAGAGCACATAATTTTATTCAAACCATTTATGGAACC CCTCTAAAGGAAGAAGAAAAAGAGGTGGTAAGACTCATGGTTATTAAACTTTTAAAAAAA AAAGTCGACAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGA 1131 n.t.

The amino acid sequences of the recombinant antigens expressed from the transgenes in Table 2 are shown in Table 3.

sequence number denomination Sequence Listing (N-ter -> C-ter) note 7 p22-TM
polypeptide MSDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLN IDQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQLKEFLDANLAGSGSGHMHHHH HHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDDKAMADIGSYKKQQPPKKVCKVDK DCGSGEHCVRGSCSSLSCLDAVKMDKRNIK IDSKISSCEFTPNFYRFTDTAADEQQEFGK TRHPIKITPSPSESHSPQEVCEKYCSWGTDDCTGWEYVGDEKEGTCYVYNNPHHPVLKYG KDHIIALPRNHKHALEHHHHHH 322 aa 8 p30
polypeptide MSDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLN IDQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQLKEFLDANLAGSGSGHMHHHH HHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDDDKAMADIGSEFMDFILNISMKMEV IFKTDLRSSSQVVFHAGSLYNWFSVE IINSGRIVTTAIKTLLSTVKYDIVKSARIYAGQG YTEHQAQEEWNMILHVLFEEETESSASSENIHEKNDNETNECTSSFETLFEQEPSSEVPK DSKLYMLAQKTVQHIEQYGKAPDFNKVIRAHNFIQTIYGTPLKEEEKEVVRLMVIKLLKK KVDKLAAALEHHHHHH 376 aa

Experimental Example 2. Expression of ASFV recombinant antigen

Expression of the recombinant antigen was confirmed by transforming E. coli expressing BL21(DE3) with the p22-TM plasmid and the p30 plasmid.

When the OD600 value was 0.5, induction was performed with 1 mM isopropyl β-thiogalactopyranoside (Isopropyl βIPTG) and incubated at 37° C. for 4 hours. Thereafter, the culture medium was harvested by centrifugation at 6,000 rpm, 15 minutes, and 4 °C. To confirm the expression of the recombinant antigen, SDS-PAGE (Sodium dodecyl sulfate-Polyacrylamide Gel Electrophoresis) was performed, and the results are shown in FIGS. 3a and 3b.

As can be seen in Figures 3a and 3b, the bands of Lane 3 and Lane 4 were dark, indicating that each ASFV recombinant antigen was properly expressed.

Experimental Example 3. Purification of ASFV recombinant antigen

The recombinant antigen (antigen protein) was purified by nickel (Ni) affinity chromatography using a 6X His tag present at the C-terminus of the recombinant antigen. Chromatographic purification was performed using AKTA Start (GE Healthcare). A HiTrap Chelating HP column (GE Healthecare) was washed with distilled water (DW) after flowing 0.1 M NiSO ₄ [Nickel(II) sulfate] solution to prepare the column.

For purification of the recombinant antigen, E. coli precipitates were suspended in a 50 mM Tris-base, 150 mM NaCl pH 8.7 solution containing 20 mM imidazole. The suspended E. coli precipitate was disrupted using a sonicator and then centrifuged at 12,578 x g for 10 minutes (A50S-8 No.7 Rotor, Hanil) to obtain a supernatant (protein extract).

The protein extract was filtered through a Millipore 0.45 um syringe filter and loaded onto a HiTrap Chelating HP column (GE Healthcare) equilibrated with 50 mM Tris-base and 150 mM NaCl pH 8.7 buffer containing 20 mM imidazole. .

The protein bound to the beads on the column was washed with a 50 mM Tris-base, 150 mM NaCl pH 8.7 wash buffer containing 100 mM imidazole, and then the recombinant antigen was eluted with a buffer containing 500 mM imidazole. The eluted protein was incubated in 50 mM Carbonate-Bicarbonate pH 9.6 buffer once overnight and once for 6 hours using 14 kDa cut-off dialtsis tubing (Sigma). dialyzed once.

The dialyzed protein was recovered and quantified using a BCA protein assay kit (Thermo Scientific), and the purity of the protein (antigen protein) was confirmed by SDS-PAGE. The results are shown in FIGS. 4a and 4b and Table 4.

BSA Control ASFV p22
(2-fold dilution) ASFV p30
(undiluted solution) A 1,940.2 1,902.7 1,088.3 B 1,078.1 1,114.9 624.7 C 571.3 519.7 295.5 D 289.5 260.3 81.6 E 123.5 95.1 <Min F 38.6 <Min <Min G <Min <Min <Min H <Min <Min <Min

As shown in Table 4, the concentration of the ASFV antigen sample was calculated as the average value obtained by multiplying the absorbance values of A and B wells by the sample dilution rate, and the concentration of the BSA control was 2 mg/mL. As for the antigen sample dilution method, A well was a numerical value obtained without dilution, and a numerical value was obtained by diluting the antigen sample by binary dilution from B to H wells. According to this calculation method, the concentration of ASFV p22 antigen was 4.1 mg/mL and the concentration of ASFV p30 was 1.2 mg/mL.

Experimental Example 4. Preparation and performance evaluation of antibody diagnostic kit using ASFV recombinant antigen

4-1. Establishment of ASFV infection-positive sera

Ten normal pigs of about 8 weeks of age were prepared. Pigs were divided into 2 groups of 5 heads, and ASF OURT 88/3 virus [attenuated ASFV (genotype I)] was inoculated into 1 group by intramuscular injection as much as 10 ⁴ TCID50 (Tissue Culture Infective Dose 50%) (Table 5 Individual numbers 8-6 to 8-10), and the other 1 group was inoculated with 10 HAD ⁵⁰ /ml of Paju primary [domestic ASFV (genotype II)] virus by intramuscular injection (object number in Table 6). 7-1 to 7-5).

After inoculation, blood was collected over time from 0 to 28 days to separate serum, and the serum titer was evaluated by measuring ASFV antibody using ELISA (Enzyme-Linked Immunosorbent Assay) and IPT (Indirect Immunoperoxidase Test). The evaluation results are shown in Tables 5 and 6.

individual
number DPI ^* 0 3 5 7 8 9 11 12 13 14 28 8-6 IPT
Titer - - - - 40 times 40 times 400 times 400 times 400 times 400 times 4,000 times 8-7 IPT Titer - - - - 40 times 40 times 400 times 400 times 400 times 400 times N/T ^** 8-8 IPT Titer - - - 40 times 40 times 40 times 400 times 400 times 400 times 400 times 4,000 times 8-9 IPT Titer - - - - - 400 times 400 times 400 times 4,000 times 4,000 times 40,000 times 8-10 IPT Titer - - - - - 40 times 40 times 400 times 40 times 400 times 40,000 times

DPI ^* : Day of post-infection, N/T ^** : Death

Individual numbers 8-7 in Table 5 were euthanized after 14 days of inoculation.

individual
number DPI 0 3 5 7 8 9 11 12 13 14 15 17 7-1 IPT
Titer - - - - - - 40 times N/T N/T N/T N/T N/T 7-2 IPT Titer - - - - 40 times N/T N/T N/T N/T N/T N/T N/T 7-3 IPT Titer - - - - - 40 times 40 times N/T N/T N/T N/T N/T 7-4 IPT Titer - - - - N/T N/T N/T N/T N/T N/T N/T N/T 7-5 IPT Titer - - - - - - - 40 times 40 times 40 times 40 times 40 times

All individuals in Table 6 died after 7 to 17 days of inoculation.

4-2. Establishment of ASFV-negative sera

Outdoor samples (541 samples) in 2017 in the United States, an area where ASFV did not occur, and outdoor samples (592 samples) in 2012, before ASFV occurred in Korea, were collected and used for evaluation.

4-3. Construction of ASFV antigen protein immobilization kit

As shown in Table 7, the concentration of the ASFV antigen protein on the plate was set to an experimental value obtained by varying the mixing ratio of the ASFV antigen protein p22 and p30. As a result of comparing the antigen protein mixing ratio, the mixing ratio most sensitive to the diluted sample (Sample 1) of ASFV-infected serum sold by ID.vet was p22 at a concentration of 0.50 ug/mL and p30 at a concentration of 1.00 ug/mL. It was found that the experimental conditions were mixed at a concentration of mL.

Example 1 Example 2 Example 3 Antigen coating concentration p22 (0.50 ug/mL)+
p30 (1.00 μg/mL) p22 (0.25 ug/mL) +
p30 (0.50 μg/mL) p22 (1.00 ug/mL)+
p30 (2.00 μg/mL) Sample O.D. S/P
Value O.D. S/P
Value O.D. S/P
Value Sample 1-1 2.587 1.62 2.572 1.49 2.917 1.57 Sample 1-2 1.955 1.23 1.811 1.05 2.161 1.17 Sample 1-3 1.308 0.82 1.165 0.67 1.352 0.73 Sample 1-4 0.895 0.56 0.782 0.45 0.952 0.51 Sample 1-5 0.566 0.36 0.533 0.31 0.596 0.32 Sample 1-6 0.318 0.20 0.302 0.17 0.353 0.19 Sample 1-7 0.225 0.14 0.196 0.11 0.255 0.14 Sample 1-8 0.163 0.10 0.141 0.08 0.196 0.11

Accordingly, ASFV antigen protein p22 [expression host cell BL21 (DE3)] at a concentration of 0.50 ug/mL and p30 [expression host cell BL21 (DE3)] at a concentration of 1.00 ug/mL were placed in a 96-well microplate. After adding 100 ul per well to attach to the plate surface, unreacted recombinant antigen proteins were removed by washing.

After dispensing 200 ul of 1% Casein-PBS-T blocking solution per well and reacting at 25 ° C for 2 hours, phosphate buffer-tween 20 [0.05% tween-20 (v / v%) phosphoric acid containing buffer solution, pH 7.4; Hereinafter, washed three times with [PBS-T] to prepare a kit.

4-4. Enzyme immunoassay reactivity evaluation test

(1) HRPO conjugate preparation

Protein A (Microprotein, cat. no. A100L20) and horseradish peroxidase (HRP) conjugated HRPO conjugate (Conjugate) were mixed with conjugate dilution buffer (Phosphate buffer solution-tween 20 0.05%, pH 7.4) It was diluted to 5 ng/ml and used.

(2) Specimen dilution buffer

PBS-T was used as a sample dilution buffer for diluting porcine serum samples.

(3) Evaluation of reactivity

After diluting 1:100 antiserum by ASFV infection and various negative antisera in the kit, 100 ul each was added to each well of a 96-well plate, reacted at room temperature (25 ± 3 ° C) for 45 minutes, and 3 times with PBS-T solution. Unreacted samples were removed by washing.

Next, the HRPO conjugate was added at a concentration of 0.005 ug/mL, reacted at room temperature (25 ± 3 °C) for 30 minutes, and washed three times with PBS-T. The HRPO conjugated antibody exhibits a color reaction by binding to an antibody against a specific antigen in a specimen. If color development does not appear, it means that there is no antibody against the specific antigen reacting with the conjugate in the sample. If there is no antibody in the specimen, no antibody binds to the coated antigen protein and no color reaction occurs.

After washing the unreacted HRPO conjugate, peroxidase substrate solution (TMB substrate solution) was added for reaction, and sulfuric acid (H ₂ SO ₄ ) 0.5 M was dispensed by 50 ul into each well of the plate. , Reactivity to the antigen was measured by measuring absorbance at 450 nm using a Sunrise ELISA reader (Tecan).

First, for ASFV gene type II (Paju isolation), the reactivity measurement results using the kit of the present invention are shown in FIG. Reactivity measurement results using are shown in Figures 6a to 6c. [The red perforated line represents the Positive cut-off line (upper dotted line), and the blue perforated line represents the Suspected cut-off line (lower dotted line)] Here, the cut-off line means a positive-negative criterion. The suspected cut-off line means a reference point for determining the false-positive interval by dividing the kit's criteria into three categories by setting a section of positive or negative, that is, not determining only two, that is, positive or negative for each product.

The experimental values of FIG. 5 are shown in Table 8, and the experimental values of FIGS. 6a to 6c are shown in Tables 9 to 11.

individual
number DPI 0 3 5 7 8 9 11 12 13 14 15 17 7-1 S/P
Value 0.07 0.07 0.07 0.07 0.13 0.40 0.87 - - - - - 7-2 S/P
Value 0.06 0.07 0.07 0.15 0.35 - - - - - - - 7-3 S/P
Value 0.06 0.07 0.08 0.10 0.23 0.67 1.21 - - - - - 7-4 S/P
Value 0.07 0.07 0.07 0.17 0.16 - - - - - - - 7-5 S/P
Value 0.08 0.07 0.06 0.07 0.07 0.07 0.09 0.07 0.08 0.08 0.13 0.13

individual
number DPI 0 3 5 7 8 9 11 12 13 14 15 17 7-1 PI (%)
Value 1.6 25.2 27.2 14.7 0.0 36.5 44.6 - - - - - 7-2 PI(%) Value 19.1 30.0 24.6 28.1 41.0 - - - - - - - 7-3 PI(%) Value 1.6 30.7 25.7 18.5 0.0 35.6 42.5 - - - - - 7-4 PI(%) Value 24.6 34.4 20.0 28.1 - - - - - - - - 7-5 PI (%)
Value 20.4 28.9 33.4 29.2 21.8 26.1 25.8 18.2 11.0 16.9 0.0 19.7

individual
number DPI 0 3 5 7 8 9 11 12 13 14 15 17 7-1 S/P (%)
Value -0.2 1.0 -0.8 0.3 3.6 7.9 4.1 - - - - - 7-2 S/P(%) Value -0.3 -1.9 0.1 2.7 5.5 - - - - - - - 7-3 S/P(%) Value 0.9 0.2 1.0 4.4 6.4 10.7 12.9 - - - - - 7-4 S/P(%) Value -1.9 -2.5 -0.6 -2.0 - - - - - - - - 7-5 S/P (%)
Value 0.2 -1.7 3.9 1.2 0.8 0.3 2.8 1.6 0.6 0.2 -3.2 1.9

individual
number DPI 0 3 5 7 8 9 11 12 13 14 15 17 7-1 S/P (%)
Value 0.6 0.7 1.2 0.6 1.6 3.8 4.5 - - - - - 7-2 S/P(%) Value 0.6 0.3 0.2 1.2 2.9 - - - - - - - 7-3 S/P(%) Value 0.7 0.7 0.9 1.6 4.5 8.9 7.7 - - - - - 7-4 S/P(%) Value 1.1 0.6 0.4 1.0 - - - - - - - - 7-5 S/P(%) Value 0.6 0.0 0.7 0.5 0.2 0.0 0.3 0.6 0.5 0.2 0.0 0.0

As can be seen in Figures 5 and 6a to 6c and Tables 8 to 11, the kit of the present invention, in which the plate is coated with ASFV recombinant antigen (p22 + p30) for gene type II specimens, has a significantly higher level than conventional commercially available kits. showed reactivity.

Next, for ASFV gene type I (OURT 88/3), the reactivity measurement results using the kit of the present invention are shown in Figure 7, and commercially available conventional kits (ID Screen Confirmation ELISA, ID Screen Competition ELISA and INgezim PPA The reactivity measurement results using COMPAC ELISA) are shown in FIGS. 8a to 8c.

The experimental values of FIG. 7 are shown in Table 12, and the experimental values of FIGS. 8A to 8C are shown in Tables 13 to 15.

individual
number DPI 0 3 5 7 8 9 11 12 13 14 28 8-6 S/P
Value 0.09 0.08 0.10 0.15 0.19 0.25 0.69 1.02 1.23 1.11 1.54 8-7 S/P
Value 0.05 0.07 0.06 0.12 0.26 0.55 1.08 1.34 1.56 1.61 - 8-8 S/P
Value 0.05 0.07 0.07 0.49 0.95 1.49 1.83 1.94 2.07 1.92 1.49 8-9 S/P
Value 0.07 0.08 0.07 0.10 0.08 0.54 1.28 1.52 1.56 1.73 1.59 8-10 S/P
Value 0.06 0.08 0.07 0.09 0.21 0.44 0.97 1.18 1.32 1.22 1.74

individual
number DPI 0 3 5 7 8 9 11 12 13 14 28 8-6 Blocking (%)
Value 29.4 34.4 37.1 39.1 53.6 56.1 70.3 69.2 70.2 74.8 85.9 8-7 Blocking(%) Value 33.2 35.4 39.2 27.6 38.7 53.7 76.4 67.2 65.0 53.7 - 8-8 Blocking(%) Value 27.8 36.9 38.1 43.8 57.1 67.4 74.3 68.9 66.2 65.5 74.3 8-9 Blocking(%) Value 31.1 33.8 34.5 28.8 27.9 46.8 66.1 66.9 71.1 70.7 90.9 8-10 Blocking (%)
Value 36.9 34.4 24.3 37.9 55.7 64.5 80.6 79.8 81.0 80.0 91.0

individual
number DPI 0 3 5 7 8 9 11 12 13 14 28 8-6 S/P (%)
Value 1.0 1.9 2.4 6.9 11.8 13.7 53.2 34.1 70.3 60.4 95.3 8-7 S/P(%) Value -1.3 -1.1 -0.8 7.5 14.0 15.5 30.2 36.9 54.8 47.7 - 8-8 S/P(%) Value -0.4 0.7 2.5 23.4 29.5 26.8 50.7 51.7 56.2 58.8 85.4 8-9 S/P (%)
Value 4.8 2.4 5.1 8.8 -2.1 17.6 55.1 61.4 66.5 73.4 102.2 8-10 S/P (%)
Value 1.9 1.2 1.2 13.4 25.5 32.1 34.5 79.6 77.5 76.9 107.7

individual
number DPI 0 3 5 7 8 9 11 12 13 14 28 8-6 PI (%)
Value 1.0 0.6 1.0 1.9 5.4 0.8 40.2 48.6 56.1 69.1 86.6 8-7 PI(%) Value 0.2 0.3 0.3 5.4 17.6 9.6 43.7 52.7 62.2 60.3 - 8-8 PI(%) Value 0.5 0.4 0.9 11.8 27.0 26.1 50.7 54.2 64.2 65.7 81.0 8-9 PI(%) Value 3.4 3.9 3.9 6.8 0.9 32.9 46.7 47.9 61.5 68.1 91.4 8-10 PI(%) Value 0.9 0.6 1.0 11.0 19.4 13.7 48.1 58.2 64.2 69.6 65.2

As can be seen in FIGS. 7 and 8a to 8c and Tables 12 to 15, unlike the results for the gene type II sample, the kit of the present invention showed similar reactivity to the conventional commercially available kit for the gene type I sample.

Next, the results of reacting the antiserum in the ASFV non-occurring region are shown in FIG. 9 and Table 16.

S/P values 0-0.1 0.1-0.2 0.2-0.25 0.25-0.3 0.3-0.4 0.4-0.5 0.5-0.6 0.6-0.7 Frequency
(n) 956 171 4 One One 0 0 0

As can be seen in Figure 9 and Table 16, the kit of the present invention coated with ASFV recombinant antigen (p22+p30) was negative for 99.8% (n = 1,133) of the antiserum.

Therefore, the kit coated with the p22 and p30 antigen proteins (two types) of the present invention can detect ASFV infection quickly and easily, and can be detected with high accuracy as it is negative for antiserum in areas where ASFV does not occur. ASFV infection can be determined.

delete

<110> MEDIAN Diagnostics Inc. REPUBLIC OF KOREA (Animal and Plant Quarantine Agency) <120> COMPOSITION FOR DIAGNOSTIC AFRICAN SWINE FEVER USING TWO RECOMBINANT ANTIGENS AND DIAGNOSTIC KITS COMPRISING THEREOF <130> PN210072 <160> 8 <170> KoPatentIn 3.0 <210> 1 <211> 30 <212> DNA <213> artificial sequence <220> <223> ASFV p22 Forward <400> 1 cgggatccta taagaaacaa caaccaccga 30 <210> 2 <211> 30 <212> DNA <213> artificial sequence <220> <223> ASFV p22 Reverse <400> 2 ccctcgagtg catgtttatg atttctaggt 30 <210> 3 <211> 45 <212> DNA <213> artificial sequence <220> <223> ASFV p30 Forward <400> 3 aacggattta agatcatctt cacaagttgt gtttcatgcg ggtag 45 <210> 4 <211> 45 <212> DNA <213> artificial sequence <220> <223> ASFV p30 Reverse <400> 4 ctacccgcat gaaacacaac ttgtgaagat gatcttaaat ccgtt 45 <210> 5 <211> 969 <212> DNA <213> unknown <220> <223> p22-TM nucleotide <400> 5 atgagcgata aaattattca cctgactgac gacagttttg acacggatgt actcaaagcg 60 gacggggcga tcctcgtcga tttctgggca gagtggtgcg gtccgtgcaa aatgatcgcc 120 ccgattctgg atgaaatcgc tgacgaatat cagggcaaac tgaccgttgc aaaactgaac 180 atcgatcaaa accctggcac tgcgccgaaa tatggcatcc gtggtatccc gactctgctg 240 ctgttcaaaa acggtgaagt ggcggcaacc aaagtgggtg cactgtctaa aggtcagttg 300 aaagagttcc tcgacgctaa cctggccggt tctggttctg gccatatgca ccatcatcat 360 catcattctt ctggtctggt gccacgcggt tctggtatga aagaaaccgc tgctgctaaa 420 ttcgaacgcc agcacatgga cagcccagat ctgggtaccg acgacgacga caaggccatg 480 gctgatatcg gatcctataa gaaacaacaa ccaccgaaaa aggtctgtaa agtagataaa 540 gattgtggta gtggagagca ttgtgttcgt ggatcatgta gctcattgag ctgcttagat 600 gccgtaaaaa tggacaaacg aaatattaag atagattcta agatttcctc atgcgaattc 660 actcccaatt tttaccgttt tacggatact gctgctgatg agcagcaaga atttggaaaa 720 acacggcatc ctataaaaat aactccatct ccaagtgaat cccatagccc ccaagaggtg 780 tgtgaaaaat attgttcatg gggaaccgat gactgtacag gttgggaata tgttggtgat 840 gaaaaggagg gaacatgtta tgtatataat aatccacatc acccggttct taaatatggt 900 aaggatcaca tcatagcctt acctagaaat cataaacatg cactcgagca ccaccaccac 960 caccactga 969 <210> 6 <211> 1131 <212> DNA <213> unknown <220> <223> p30 nucleotide <400> 6 atgagcgata aaattattca cctgactgac gacagttttg acacggatgt actcaaagcg 60 gacggggcga tcctcgtcga tttctgggca gagtggtgcg gtccgtgcaa aatgatcgcc 120 ccgattctgg atgaaatcgc tgacgaatat cagggcaaac tgaccgttgc aaaactgaac 180 atcgatcaaa accctggcac tgcgccgaaa tatggcatcc gtggtatccc gactctgctg 240 ctgttcaaaa acggtgaagt ggcggcaacc aaagtgggtg cactgtctaa aggtcagttg 300 aaagagttcc tcgacgctaa cctggccggt tctggttctg gccatatgca ccatcatcat 360 catcattctt ctggtctggt gccacgcggt tctggtatga aagaaaccgc tgctgctaaa 420 ttcgaacgcc agcacatgga cagcccagat ctgggtaccg acgacgacga caaggccatg 480 gctgatatcg gatccgaatt catggatttt attttaaata tatccatgaa aatggaggtc 540 atcttcaaaa cggatttaag atcatcttca caagttgtgt ttcatgcggg tagtctgtat 600 aattggtttt ctgttgagat tatcaatagc ggtagaattg ttacgaccgc tataaaaaca 660 ttgcttagta ctgttaagta tgatattgtg aaatctgctc gtatatatgc agggcaaggg 720 tatactgaac atcaggctca agaagaatgg aatatgattc tgcatgtgct gtttgaagag 780 gagacggaat cctcagcatc ttcggagaac attcatgaaa aaaatgataa tgaaaccaat 840 gaatgcacat cctcctttga aacgttgttt gagcaagagc cctcatcgga ggtacctaaa 900 gactccaagc tgtatatgct tgcacaaaag actgtgcaac atattgaaca atatggaaag 960 gcacctgatt ttaacaaggt tattagagca cataatttta ttcaaaccat ttatggaacc 1020 cctctaaagg aagaagaaaa agaggtggta agactcatgg ttattaaact tttaaaaaaa 1080 aaagtcgaca agcttgcggc cgcactcgag caccaccacc accaccactg a 1131 <210> 7 <211> 322 <212> PRT <213> unknown <220> <223> p22-TM polypeptide <400> 7 Met Ser Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp 1 5 10 15 Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp 20 25 30 Cys Gly Pro Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp 35 40 45 Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn 50 55 60 Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu 65 70 75 80 Leu Phe Lys Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu Ser 85 90 95 Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala Gly Ser Gly 100 105 110 Ser Gly His Met His His His His His His Ser Ser Gly Leu Val Pro 115 120 125 Arg Gly Ser Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln 130 135 140 His Met Asp Ser Pro Asp Leu Gly Thr Asp Asp Asp Asp Lys Ala Met 145 150 155 160 Ala Asp Ile Gly Ser Tyr Lys Lys Gln Gln Pro Pro Lys Lys Val Cys 165 170 175 Lys Val Asp Lys Asp Cys Gly Ser Gly Glu His Cys Val Arg Gly Ser 180 185 190 Cys Ser Ser Leu Ser Cys Leu Asp Ala Val Lys Met Asp Lys Arg Asn 195 200 205 Ile Lys Ile Asp Ser Lys Ile Ser Ser Cys Glu Phe Thr Pro Asn Phe 210 215 220 Tyr Arg Phe Thr Asp Thr Ala Ala Asp Glu Gln Gln Glu Phe Gly Lys 225 230 235 240 Thr Arg His Pro Ile Lys Ile Thr Pro Ser Pro Ser Glu Ser His Ser 245 250 255 Pro Gln Glu Val Cys Glu Lys Tyr Cys Ser Trp Gly Thr Asp Asp Cys 260 265 270 Thr Gly Trp Glu Tyr Val Gly Asp Glu Lys Glu Gly Thr Cys Tyr Val 275 280 285 Tyr Asn Asn Pro His His Pro Val Leu Lys Tyr Gly Lys Asp His Ile 290 295 300 Ile Ala Leu Pro Arg Asn His Lys His Ala Leu Glu His His His His 305 310 315 320 His His <210> 8 <211> 376 <212> PRT <213> unknown <220> <223> p30 polypeptide <400> 8 Met Ser Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp 1 5 10 15 Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp 20 25 30 Cys Gly Pro Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp 35 40 45 Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn 50 55 60 Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu 65 70 75 80 Leu Phe Lys Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu Ser 85 90 95 Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala Gly Ser Gly 100 105 110 Ser Gly His Met His His His His His His Ser Ser Gly Leu Val Pro 115 120 125 Arg Gly Ser Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln 130 135 140 His Met Asp Ser Pro Asp Leu Gly Thr Asp Asp Asp Asp Lys Ala Met 145 150 155 160 Ala Asp Ile Gly Ser Glu Phe Met Asp Phe Ile Leu Asn Ile Ser Met 165 170 175 Lys Met Glu Val Ile Phe Lys Thr Asp Leu Arg Ser Ser Ser Gln Val 180 185 190 Val Phe His Ala Gly Ser Leu Tyr Asn Trp Phe Ser Val Glu Ile Ile 195 200 205 Asn Ser Gly Arg Ile Val Thr Thr Ala Ile Lys Thr Leu Leu Ser Thr 210 215 220 Val Lys Tyr Asp Ile Val Lys Ser Ala Arg Ile Tyr Ala Gly Gln Gly 225 230 235 240 Tyr Thr Glu His Gln Ala Gln Glu Glu Trp Asn Met Ile Leu His Val 245 250 255 Leu Phe Glu Glu Glu Thr Glu Ser Ser Ala Ser Ser Glu Asn Ile His 260 265 270 Glu Lys Asn Asp Asn Glu Thr Asn Glu Cys Thr Ser Ser Phe Glu Thr 275 280 285 Leu Phe Glu Gln Glu Pro Ser Ser Glu Val Pro Lys Asp Ser Lys Leu 290 295 300 Tyr Met Leu Ala Gln Lys Thr Val Gln His Ile Glu Gln Tyr Gly Lys 305 310 315 320 Ala Pro Asp Phe Asn Lys Val Ile Arg Ala His Asn Phe Ile Gln Thr 325 330 335 Ile Tyr Gly Thr Pro Leu Lys Glu Glu Glu Lys Glu Val Val Arg Leu 340 345 350 Met Val Ile Lys Leu Leu Lys Lys Lys Val Asp Lys Leu Ala Ala Ala 355 360 365 Leu Glu His His His His His His 370 375

Claims (8)

A peptide containing the amino acid sequence of SEQ ID NO: 7 at a concentration of 0.50 ug/mL; and
A concentration of 1.00 ug/mL of the peptide comprising the amino acid sequence of SEQ ID NO: 8;
An antigenic composition for simultaneous diagnosis of African swine fever (ASF) type I and type II comprising the. delete delete A peptide containing the amino acid sequence of SEQ ID NO: 7 at a concentration of 0.50 ug/mL; and
A concentration of 1.00 ug/mL of the peptide comprising the amino acid sequence of SEQ ID NO: 8;
A kit for simultaneous diagnosis of African swine fever (ASF) type I and type II, comprising: According to claim 4, wherein the kit further comprises a chromogenic enzyme, African swine fever (ASF) type I and II simultaneous diagnosis kit. The method of claim 5, wherein the chromogenic enzyme is Q dot (Quantum dot), HRPO (Horseradish peroxidase), basic dephosphorylation enzyme (Alkaline phosphatase), glucose oxidase (Glucose Oxidase), luciferase (luciferase), beta-di -African pig, in which protein A is conjugated with one enzyme selected from the group consisting of β-malate dehydrogenase (MDH) and acetylcholinesterase A kit for the simultaneous diagnosis of fever (ASF) types I and II. A method of providing information for the simultaneous diagnosis of African swine fever (ASF) types I and II, which includes the following steps:
preparation step of preparing a sample; and
A contacting step of contacting the sample with a composition comprising the peptide comprising the amino acid sequence of SEQ ID NO: 7 at a concentration of 0.50 ug/mL and the peptide comprising the amino acid sequence of SEQ ID NO: 8 at a concentration of 1.00 ug/mL. The information providing method according to claim 7, wherein the contacting step is performed at a temperature condition of 20 to 30 °C.

Images